Skip to content

SPAC Feed

Curated SPACs News

  • News
  • Opinions
  • Events
  • Videos
  • Resources
  • Contact Us

Tag: Globe Newswire

  • Home
  • Globe Newswire
  • Page 3
  • Nasdaq:SABS
  • Nasdaq:SABSW
  • US78397T1034
Posted on March 17, 2026

SAB BIO Announces Pricing of $85 Million Public Offering of Common Stock and Pre-Funded Warrants

MIAMI, March 17, 2026 (GLOBE NEWSWIRE) — SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type…

By sf-admin
  • CA98420N1050
  • Nasdaq:XENE
Posted on March 10, 2026

Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

VANCOUVER, British Columbia and BOSTON, March 10, 2026 (GLOBE NEWSWIRE) — Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical…

By sf-admin
  • Nasdaq:PVLA
  • US6979471090
Posted on March 2, 2026

Palvella Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

WAYNE, Pa., March 02, 2026 (GLOBE NEWSWIRE) — Palvella Therapeutics, Inc. (“Palvella”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies…

By sf-admin
  • Nasdaq:LRMR
  • US5171251003
Posted on February 25, 2026

Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering

BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) — Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex…

By sf-admin
  • Nasdaq:GLPI
  • US36467J1088
Posted on February 25, 2026

Gaming and Leisure Properties Announces Pricing of $800,000,000 of 5.625% Senior Notes Due 2036

WYOMISSING, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) — Gaming and Leisure Properties, Inc. (“GLPI”) (NASDAQ: GLPI) today announced the pricing of a public offering of…

By sf-admin
Uncategorized Posted on February 24, 2026

MBody AI and Check Cap Ltd. ($MBAI) Submit Nasdaq Listing Application for Merger Close

Proposed Nasdaq-listed AI company achieves key regulatory milestone as merger with Check-Cap targets first half of 2026; $30M growth facility available. Source: MBody AI and…

By sf-admin
  • CA29842P1053
  • Nasdaq:EPRX
  • TSX:EPRX
Posted on February 20, 2026

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option Source: Eupraxia Pharmaceuticals Announces Closing of US.2 Million Public Offering…

By sf-admin
  • Nasdaq:SOPA
  • US83370P1021
Posted on February 11, 2026

Society Pass Incorporated Announces Pricing of $3.0 Million Public Offering of Common Stock

NEW YORK, Feb. 11, 2026 (GLOBE NEWSWIRE) — Society Pass Incorporated (Nasdaq: SOPA) (the “Company”), Southeast Asia’s (SEA) next generation e-commerce ecosystem, today announced the…

By sf-admin
  • Nasdaq:ARKO
  • US0412421085
Posted on February 11, 2026

ARKO Corp. and ARKO Petroleum Corp. Announce Pricing of ARKO Petroleum Corp.’s Initial Public Offering

RICHMOND, Va., Feb. 11, 2026 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO”) and ARKO Petroleum Corp., a subsidiary of ARKO (“APC”), today announced the…

By sf-admin
  • Nasdaq:MWH
  • TEMPISIN1234
Posted on February 10, 2026

SOLV Energy Announces Pricing of Initial Public Offering

SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) — SOLV Energy, Inc. (“SOLV” or the “Company”), a leading provider of infrastructure services to the power industry,…

By sf-admin
  • Nasdaq:LXRX
  • US5288723027
Posted on February 6, 2026

Lexicon Announces Closing of Approximately $94.6 Million Public Offering and Concurrent Private Placement

THE WOODLANDS, Texas, Feb. 06, 2026 (GLOBE NEWSWIRE) — Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the closing of its previously announced underwritten public…

By sf-admin
  • Nasdaq:AGMB
  • US00860C1027
Posted on February 5, 2026

Agomab Announces Pricing of Initial Public Offering

Agomab today announced the pricing of its initial public offering of 12,500,000 ADSs representing 12,500,000 of its common shares. Source: Agomab Announces Pricing of Initial…

By sf-admin
  • 123412341234
  • Nasdaq:SGP
Posted on February 5, 2026

SpyGlass Pharma Announces Pricing of Initial Public Offering

ALISO VIEJO, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) — SpyGlass Pharma, Inc. (Nasdaq: SGP) (“SpyGlass Pharma”), a late-stage biopharmaceutical company, today announced the pricing of…

By sf-admin
  • Nasdaq:EIKN
  • TEMP12345678
Posted on February 4, 2026

Eikon Therapeutics Announces Pricing of Upsized Initial Public Offering

MILLBRAE, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) — Eikon Therapeutics, Inc. (“Eikon”), a late-stage clinical biopharmaceutical company dedicated to developing important, innovative medicines to address…

By sf-admin
  • Nasdaq:ARKO
  • US0412421085
Posted on February 3, 2026

ARKO Corp. Announces Launch of Initial Public Offering of its Subsidiary, ARKO Petroleum Corp., Seeking to Raise Approximately $200,000,000

RICHMOND, Va., Feb. 03, 2026 (GLOBE NEWSWIRE) — ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”) today announced that its subsidiary, ARKO Petroleum Corp. (“APC”),…

By sf-admin
  • Nasdaq:PLYX
  • US73185E1055
Posted on February 2, 2026

Polaryx Therapeutics Announces Direct Listing on Nasdaq; Shares to Begin Trading Under the Symbol “PLYX”

PARAMUS, NJ, Feb. 02, 2026 (GLOBE NEWSWIRE) — Polaryx Therapeutics (“Polaryx” or the “Company”) a clinical-stage biotechnology company dedicated to the discovery, development, and commercialization…

By sf-admin
  • KYG9833K1287
  • Nasdaq:XSLLU
Posted on January 30, 2026

Xsolla SPAC 1 Announces Closing of $200,000,000 Initial Public Offering

Sherman Oaks, CA, Jan. 30, 2026 (GLOBE NEWSWIRE) — Xsolla SPAC 1 (the “Company”), a newly organized special purpose acquisition company formed as a Cayman…

By sf-admin
  • Nasdaq:ALT
  • US02155H1014
Posted on January 29, 2026

Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock

GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced…

By sf-admin
Uncategorized Posted on January 28, 2026

Ethos Announces Pricing of Initial Public Offering

Ethos Announces Pricing of Initial Public Offering Source: Ethos Announces Pricing of Initial Public Offering

By sf-admin
  • NYSE:LODE
  • US2057501023
Posted on January 28, 2026

Comstock Inc. Prices $50 Million Upsized and Oversubscribed Public Offering of Common Stock

VIRGINIA CITY, Nev., Jan. 28, 2026 (GLOBE NEWSWIRE) — Comstock Inc. (NYSE: LODE) (“Comstock” and the “Company”), today announced that it has priced its previously…

By sf-admin

Posts navigation

Older
Next


  • About Us
  • Contact Us
  • Subscribe
Copyright © 2026 SPAC Feed. All Rights Reserved | News Vibe by Theme Palace